Quantum Biopharma (NASDAQ:QNTM) Announces Earnings Results, Misses Estimates By $1.05 EPS

Quantum Biopharma (NASDAQ:QNTM) posted its quarterly earnings results on Friday. The company reported ($1.25) EPS for the quarter, missing the consensus estimate of ($0.20) by ($1.05), Zacks reports.

Quantum Biopharma Stock Up 3.7%

Shares of NASDAQ:QNTM traded up $0.32 during midday trading on Friday, reaching $8.91. 40,765 shares of the company were exchanged, compared to its average volume of 73,794. The firm has a market cap of $34.00 million, a PE ratio of -0.64 and a beta of 0.54. Quantum Biopharma has a fifty-two week low of $2.70 and a fifty-two week high of $38.25. The stock has a fifty day simple moving average of $15.04 and a two-hundred day simple moving average of $16.64.

Wall Street Analyst Weigh In

Several research firms recently commented on QNTM. Wall Street Zen downgraded Quantum Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, November 1st. Weiss Ratings reissued a “sell (e+)” rating on shares of Quantum Biopharma in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Quantum Biopharma Company Profile

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS.